Introduction to Recombinant Human LITAF/PIG7/SIMPLE Protein
Recombinant Human LITAF/PIG7/SIMPLE Protein, also known as Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF), Phosphatidylinositol glycan anchor biosynthesis class F protein (PIG7), or Small integral membrane protein of lysosome/late endosome (SIMPLE), is a protein that plays a crucial role in the immune response and cellular processes. This protein is encoded by the LITAF gene, located on chromosome 16 in humans. Recombinant Human LITAF/PIG7/SIMPLE Protein is produced using recombinant DNA technology, making it a valuable tool for research and therapeutic applications.
Structure of Recombinant Human LITAF/PIG7/SIMPLE Protein
Recombinant Human LITAF/PIG7/SIMPLE Protein is a 161 amino acid protein with a molecular weight of approximately 18.5 kDa. It contains a single transmembrane domain and is predominantly localized in the endosomal and lysosomal compartments of the cell. The protein structure consists of an N-terminal domain, a central domain, and a C-terminal domain. The N-terminal domain is responsible for the protein’s interaction with other cellular proteins, while the central domain is involved in the regulation of cellular processes. The C-terminal domain is responsible for the protein’s transmembrane localization and is essential for its function.
Activity of Recombinant Human LITAF/PIG7/SIMPLE Protein
Recombinant Human LITAF/PIG7/SIMPLE Protein is primarily known for its role in the immune response. It is involved in the production of cytokines, such as tumor necrosis factor-alpha (TNF-α), which play a crucial role in inflammation and host defense against pathogens. The protein is also involved in the regulation of autophagy, a process that helps in the removal of damaged or unnecessary cellular components. Additionally, Recombinant Human LITAF/PIG7/SIMPLE Protein has been shown to play a role in lipid metabolism and cellular signaling pathways.
Recent studies have also suggested a potential role of Recombinant Human LITAF/PIG7/SIMPLE Protein in cancer. It has been shown to be upregulated in various types of cancer, and its overexpression has been linked to tumor growth and metastasis. Further research is needed to fully understand the role of this protein in cancer and its potential as a therapeutic target.
Application of Recombinant Human LITAF/PIG7/SIMPLE Protein
Recombinant Human LITAF/PIG7/SIMPLE Protein has various applications in both research and therapeutic settings. Its role in the immune response makes it a valuable tool for studying the mechanisms of inflammation and host defense against pathogens. It can also be used to investigate the role of autophagy in cellular processes and its potential as a therapeutic target in diseases such as neurodegenerative disorders and cancer.
In therapeutic applications, Recombinant Human LITAF/PIG7/SIMPLE Protein has shown promising results as a potential immunotherapy for cancer. Studies have demonstrated that the protein can induce an immune response against cancer cells and inhibit tumor growth. It has also been shown to enhance the effectiveness of other cancer treatments, such as chemotherapy and radiation therapy.
Furthermore, Recombinant Human LITAF/PIG7/SIMPLE Protein has potential as a diagnostic biomarker for various diseases. Its overexpression in certain types of cancer makes it a potential marker for early detection and monitoring of disease progression.
Conclusion
Recombinant Human LITAF/PIG7/SIMPLE Protein is a multifunctional protein with important roles in the immune response, cellular processes, and potentially cancer. Its
There are no reviews yet.